Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:43
10/14/21
10/14
18:43
10/14/21
18:43
RIO

Rio Tinto

$71.09 /

+2.04 (+2.95%)

, CHPT

ChargePoint

$19.92 /

-0.07 (-0.35%)

, WTI

W&T Offshore

$4.16 /

-0.23 (-5.24%)

, CRSR

Corsair Gaming

$26.96 /

+0.65 (+2.47%)

, SPCE

Virgin Galactic

$24.06 /

+0.13 (+0.54%)

, TACO

Del Taco

$9.40 /

+0.44 (+4.91%)

, DCT

Duck Creek Technologies

$46.23 /

+0.53 (+1.16%)

, LTH

Life Time Group

$17.29 /

-0.12 (-0.69%)

, TRQ

Turquoise Hill

$15.42 /

+0.255 (+1.68%)

, GTHX

G1 Therapeutics

$12.66 /

+0.07 (+0.56%)

, ME

23andMe

$7.87 /

-0.08 (-1.01%)

, WAFD

Washington Federal

$35.27 /

+0.55 (+1.58%)

, AA

Alcoa

$48.60 /

+0.19 (+0.39%)

Check out this evening's…

ShowHide Related Items >><<
WTI W&T Offshore
$4.16 /

-0.23 (-5.24%)

WAFD Washington Federal
$35.27 /

+0.55 (+1.58%)

TRQ Turquoise Hill
$15.42 /

+0.255 (+1.68%)

TACO Del Taco
$9.40 /

+0.44 (+4.91%)

SPCE Virgin Galactic
$24.06 /

+0.13 (+0.54%)

RIO Rio Tinto
$71.09 /

+2.04 (+2.95%)

ME 23andMe
$7.87 /

-0.08 (-1.01%)

LTH Life Time Group
$17.29 /

-0.12 (-0.69%)

GTHX G1 Therapeutics
$12.66 /

+0.07 (+0.56%)

DCT Duck Creek Technologies
$46.23 /

+0.53 (+1.16%)

CRSR Corsair Gaming
$26.96 /

+0.65 (+2.47%)

CHPT ChargePoint
$19.92 /

-0.07 (-0.35%)

AA Alcoa
$48.60 /

+0.19 (+0.39%)

RIO Rio Tinto
$71.09 /

+2.04 (+2.95%)

10/11/21 JPMorgan
Rio Tinto price target lowered to 6,800 GBp from 7,210 GBp at JPMorgan
10/06/21 Exane BNP Paribas
Rio Tinto upgraded to Outperform at Exane BNP Paribas on valuation
10/06/21 Exane BNP Paribas
Rio Tinto upgraded to Outperform from Neutral at Exane BNP Paribas
09/29/21 Morgan Stanley
Rio Tinto price target lowered to 5,010 GBp from 5,410 GBp at Morgan Stanley
CHPT ChargePoint
$19.92 /

-0.07 (-0.35%)

09/23/21 Fox Advisors
ChargePoint initiated with an Equal Weight at Fox Advisors
09/08/21 BofA
ChargePoint initiated with a Neutral at BofA
09/02/21 Jefferies
ChargePoint price target lowered to $36 from $40 at Jefferies
08/01/21 Goldman Sachs
ChargePoint initiated with a Neutral at Goldman Sachs
WTI W&T Offshore
$4.16 /

-0.23 (-5.24%)

09/09/21 Roth Capital
W&T Offshore should be bought on any weakness, says Roth Capital
11/05/20 Capital One
W&T Offshore upgraded to Equalweight from Underweight at Capital One
CRSR Corsair Gaming
$26.96 /

+0.65 (+2.47%)

08/04/21
Fly Intel: Top five analyst downgrades
08/04/21 Credit Suisse
Corsair Gaming downgraded to Neutral at Credit Suisse following Q2 results
08/04/21 Baird
Corsair Gaming price target lowered to $38 from $48 at Baird
08/04/21 Barclays
Corsair Gaming price target lowered to $42 from $47 at Barclays
SPCE Virgin Galactic
$24.06 /

+0.13 (+0.54%)

10/15/21 Canaccord
Virgin Galactic flight delay not significant to long-term plans, says Canaccord
10/15/21 BofA
Virgin Galactic price target lowered to $20 from $25 at BofA
09/16/21 Cowen
Virgin Galactic price target lowered to $30 from $51 at Cowen
09/14/21 UBS
Virgin Galactic price target lowered to $26 from $38 at UBS
TACO Del Taco
$9.40 /

+0.44 (+4.91%)

03/09/21 CL King
Del Taco outpaced restaurant-level operating margin assumptions, says CL King
DCT Duck Creek Technologies
$46.23 /

+0.53 (+1.16%)

10/15/21 JPMorgan
JPMorgan downgrades Duck Creek on thesis 'cracks' post results
10/15/21 RBC Capital
Duck Creek Technologies price target lowered to $47 from $51 at RBC Capital
10/15/21 JPMorgan
Duck Creek Technologies downgraded to Neutral from Overweight at JPMorgan
10/11/21 DA Davidson
Duck Creek Technologies price target raised to $52 from $50 at DA Davidson
LTH Life Time Group
$17.29 /

-0.12 (-0.69%)

TRQ Turquoise Hill
$15.42 /

+0.255 (+1.68%)

10/15/21 Canaccord
Canaccord downgrades Turquoise Hill to Sell after 'slew of negative updates'
10/15/21 Canaccord
Turquoise Hill downgraded to Sell from Hold at Canaccord
10/12/21 Scotiabank
Turquoise Hill price target lowered to C$28 from C$30 at Scotiabank
09/17/21 Macquarie
Turquoise Hill upgraded on improved copper outlook at Macquarie
GTHX G1 Therapeutics
$12.66 /

+0.07 (+0.56%)

10/14/21 BTIG
G1 Therapeutics assumed with a Buy at BTIG
09/30/21 JPMorgan
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
ME 23andMe
$7.87 /

-0.08 (-1.01%)

08/16/21 Credit Suisse
23andMe initiated with an Outperform at Credit Suisse
08/16/21 Citi
23andMe price target lowered to $12 from $14 at Citi
07/13/21 Citi
23andMe initiated with a Buy at Citi
WAFD Washington Federal
$35.27 /

+0.55 (+1.58%)

AA Alcoa
$48.60 /

+0.19 (+0.39%)

10/15/21 B. Riley
Alcoa price target raised to $52 from $51 at B. Riley
09/28/21 Morgan Stanley
Morgan Stanley raises Alcoa price target to $62, names stock Top Pick
09/21/21 B. Riley
Alcoa price target raised to $51 from $45 at B. Riley
09/16/21 Deutsche Bank
Alcoa price target raised to $60 from $48 at Deutsche Bank
WTI W&T Offshore
$4.16 /

-0.23 (-5.24%)

WAFD Washington Federal
$35.27 /

+0.55 (+1.58%)

TRQ Turquoise Hill
$15.42 /

+0.255 (+1.68%)

TACO Del Taco
$9.40 /

+0.44 (+4.91%)

SPCE Virgin Galactic
$24.06 /

+0.13 (+0.54%)

ME 23andMe
$7.87 /

-0.08 (-1.01%)

GTHX G1 Therapeutics
$12.66 /

+0.07 (+0.56%)

DCT Duck Creek Technologies
$46.23 /

+0.53 (+1.16%)

CRSR Corsair Gaming
$26.96 /

+0.65 (+2.47%)

CHPT ChargePoint
$19.92 /

-0.07 (-0.35%)

AA Alcoa
$48.60 /

+0.19 (+0.39%)

  • 07
    Oct
  • 15
    Jul
  • 29
    Jan
  • 22
    Jan
  • 11
    Nov
SPCE Virgin Galactic
$24.06 /

+0.13 (+0.54%)

RIO Rio Tinto
$71.09 /

+2.04 (+2.95%)

CRSR Corsair Gaming
$26.96 /

+0.65 (+2.47%)

CHPT ChargePoint
$19.92 /

-0.07 (-0.35%)

WTI W&T Offshore
$4.16 /

-0.23 (-5.24%)

WAFD Washington Federal
$35.27 /

+0.55 (+1.58%)

TRQ Turquoise Hill
$15.42 /

+0.255 (+1.68%)

TACO Del Taco
$9.40 /

+0.44 (+4.91%)

SPCE Virgin Galactic
$24.06 /

+0.13 (+0.54%)

RIO Rio Tinto
$71.09 /

+2.04 (+2.95%)

ME 23andMe
$7.87 /

-0.08 (-1.01%)

LTH Life Time Group
$17.29 /

-0.12 (-0.69%)

DCT Duck Creek Technologies
$46.23 /

+0.53 (+1.16%)

CRSR Corsair Gaming
$26.96 /

+0.65 (+2.47%)

CHPT ChargePoint
$19.92 /

-0.07 (-0.35%)

AA Alcoa
$48.60 /

+0.19 (+0.39%)

WTI W&T Offshore
$4.16 /

-0.23 (-5.24%)

WAFD Washington Federal
$35.27 /

+0.55 (+1.58%)

TRQ Turquoise Hill
$15.42 /

+0.255 (+1.68%)

TACO Del Taco
$9.40 /

+0.44 (+4.91%)

SPCE Virgin Galactic
$24.06 /

+0.13 (+0.54%)

RIO Rio Tinto
$71.09 /

+2.04 (+2.95%)

ME 23andMe
$7.87 /

-0.08 (-1.01%)

DCT Duck Creek Technologies
$46.23 /

+0.53 (+1.16%)

CRSR Corsair Gaming
$26.96 /

+0.65 (+2.47%)

CHPT ChargePoint
$19.92 /

-0.07 (-0.35%)

AA Alcoa
$48.60 /

+0.19 (+0.39%)

Initiation
G1 Therapeutics assumed with a Buy at BTIG » 16:26
10/14/21
10/14
16:26
10/14/21
16:26
GTHX

G1 Therapeutics

$12.66 /

+0.07 (+0.56%)

BTIG analyst Kaveri…

BTIG analyst Kaveri Pohlman initiated coverage of G1 Therapeutics with a Buy rating and $51 price target. The analyst assumed coverage of 12 Immuno-oncology companies. Pohlman believes "much of the most promising work" involves broader immune involvement in the anti-tumor battle either involving or in combination with less-systemically toxic therapeutic cytokines. The world of allogeneic cellular therapies is "very close to catching the autologous world but that these approaches will always be complex for smaller hospitals to employ leaving this approach for a subset of patients," Pohlman tells investors in a research note.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$12.66 /

+0.07 (+0.56%)

GTHX G1 Therapeutics
$12.66 /

+0.07 (+0.56%)

09/30/21 JPMorgan
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
GTHX G1 Therapeutics
$12.66 /

+0.07 (+0.56%)

Hot Stocks
G1 Therapeutics announces results from analysis of three studies on COSELA » 08:12
10/07/21
10/07
08:12
10/07/21
08:12
GTHX

G1 Therapeutics

$12.17 /

-0.505 (-3.99%)

G1 Therapeutics announced…

G1 Therapeutics announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell lung cancer who received the drug prior to each chemotherapy treatment had significantly lower use of supportive care therapies for chemotherapy-induced myelosuppression than patients who received placebo. Results of the retrospective analysis are published in the online edition of the journal Cancer Medicine. COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. In the study, the researchers assessed the impact of trilaciclib versus placebo on subsequent use of supportive therapies following chemotherapy treatments for ES-SCLC. The results showed that trilaciclib significantly reduced the duration and occurrence of chemotherapy-induced severe neutropenia and the occurrence of grade 3 or greater chemotherapy-induced anemia, with a corresponding reduction in the use of supportive care therapies to manage these adverse events. Specifically, the analysis showed that administering trilaciclib prior to chemotherapy: Significantly reduced the occurrence of severe neutropenia-11.4% in the trilaciclib group versus 52.9% in the placebo group; with a corresponding reduction in G-CSF use by approximately half in the trilaciclib group compared with placebo; consistency of treatment effects on occurrence of severe neutropenia with or without concomitant G-CSF use was tested and results indicated that the effect of trilaciclib was consistent regardless of whether or not a G-CSF was administered. Significantly reduced the occurrence of grade 3/4 anemia compared with placebo-20.3% in the trilaciclib group versus 31.9% in the placebo group; with a corresponding reduction of ESA treatment: 3.3% trilaciclib versus 11.8% placebo and a corresponding reduction of red blood cell transfusions on or after week five: 14.6% trilaciclib versus 26.1% placebo. In a separate analysis, the use of trilaciclib significantly reduced patient hospitalizations due to chemotherapy induced myelosuppression or sepsis, with 4.1% of patients hospitalized in the trilaciclib arm versus 13.6% of patients hospitalized in the placebo arm. The findings were derived from a retrospective analysis of pooled data obtained from three randomized, Phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in 242 patients with ES-SCLC. The authors suggest that the pooled data indicate that the administration of trilaciclib prior to chemotherapy has the potential to reduce the burden of CIM on health care systems.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$12.17 /

-0.505 (-3.99%)

GTHX G1 Therapeutics
$12.17 /

-0.505 (-3.99%)

09/30/21 JPMorgan
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
GTHX G1 Therapeutics
$12.17 /

-0.505 (-3.99%)

Conference/Events
G1 Therapeutics management to meet virtually with BTIG » 04:55
10/07/21
10/07
04:55
10/07/21
04:55
GTHX

G1 Therapeutics

$12.17 /

-0.505 (-3.99%)

Virtual Meeting to be…

Virtual Meeting to be held on October 7 hosted by BTIG.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$12.17 /

-0.505 (-3.99%)

GTHX G1 Therapeutics
$12.17 /

-0.505 (-3.99%)

09/30/21 JPMorgan
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
GTHX G1 Therapeutics
$12.17 /

-0.505 (-3.99%)

Hot Stocks
G1 Therapeutics announces permanent J-Code from CMS for COSELA » 07:49
10/01/21
10/01
07:49
10/01/21
07:49
GTHX

G1 Therapeutics

$13.43 /

-1.465 (-9.84%)

G1 Therapeutics announced…

G1 Therapeutics announced that the permanent J-code for COSELA that was issued in July 2021 by the Centers for Medicare & Medicaid Services is now effective for provider billing for all sites of care. The permanent J-code for COSELA, J1448, published online on the CMS website.. J-codes are permanent, product specific reimbursement codes assigned to outpatient and physician administered "buy and bill" products under Medicare Part B and are used by commercial insurers and government payers to facilitate and standardize claims submissions and reimbursements for medications like COSELA. With the permanent J-code now in effect, all hospital outpatient departments, ambulatory surgery centers and physician offices in the United States will have one consistent Healthcare Common Procedure Coding System code to standardize the submission and payment of COSELA insurance claims across Medicare, Medicare Advantage, Medicaid and commercial plans. G1's new technology add-on payment for COSELA which provides additional payment to inpatient hospitals above the standard Medicare Severity Diagnosis-Related Group payment amount also became effective for provider billing today, October 1, 2021.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$13.43 /

-1.465 (-9.84%)

GTHX G1 Therapeutics
$13.43 /

-1.465 (-9.84%)

09/30/21 JPMorgan
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
GTHX G1 Therapeutics
$13.43 /

-1.465 (-9.84%)

Downgrade
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan » 05:15
09/30/21
09/30
05:15
09/30/21
05:15
GTHX

G1 Therapeutics

$14.88 /

-0.55 (-3.56%)

JPMorgan analyst Anup…

JPMorgan analyst Anup Rama downgraded G1 Therapeutics to Neutral from Overweight with a price target of $20, down from $24. In the near-term, the focus remains on the Cosela launch, says the analyst, who sees the product tracking to a potential Street consensus miss in Q3 and Q4. As such, there is the potential for downward revision of Cosela estimates, Rama tells investors in a research note. GI also has "no game-changing clinical catalysts" for the next 9-12 months, adds the analyst.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$14.88 /

-0.55 (-3.56%)

GTHX G1 Therapeutics
$14.88 /

-0.55 (-3.56%)

08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
11/17/20 Raymond James
G1 Therapeutics downgraded to Outperform from Strong Buy at Raymond James
GTHX G1 Therapeutics
$14.88 /

-0.55 (-3.56%)

Conference/Events
G1 Therapeutics management to meet virtually with BTIG » 10:45
09/28/21
09/28
10:45
09/28/21
10:45
GTHX

G1 Therapeutics

$15.66 /

-0.27 (-1.69%)

Virtual Meeting to be…

Virtual Meeting to be held on October 7 hosted by BTIG.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.66 /

-0.27 (-1.69%)

GTHX G1 Therapeutics
$15.66 /

-0.27 (-1.69%)

08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
11/17/20 Raymond James
G1 Therapeutics downgraded to Outperform from Strong Buy at Raymond James
GTHX G1 Therapeutics
$15.66 /

-0.27 (-1.69%)

Over a month ago
Hot Stocks
G1 Therapeutics to hire new supplemental Cosela sales force » 06:47
09/15/21
09/15
06:47
09/15/21
06:47
GTHX

G1 Therapeutics

$13.88 /

-0.97 (-6.53%)

G1 Therapeutics announced…

G1 Therapeutics announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team. The expansion will allow G1 to target top tier accounts in order to accelerate sales activities and help maximize the adoption of Cosela. The new G1 sales representatives will supplement the existing Boehringer Ingelheim oncology commercial team. G1 entered into a three-year co-promotion agreement with Boehringer Ingelheim to collaborate on the commercialization of Cosela for its first indication in ES-SCLC.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$13.88 /

-0.97 (-6.53%)

GTHX G1 Therapeutics
$13.88 /

-0.97 (-6.53%)

08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
11/17/20 Raymond James
G1 Therapeutics downgraded to Outperform from Strong Buy at Raymond James
GTHX G1 Therapeutics
$13.88 /

-0.97 (-6.53%)

Hot Stocks
G1 Therapeutics announces inducement grants under Nasdaq listing rule » 07:33
09/03/21
09/03
07:33
09/03/21
07:33
GTHX

G1 Therapeutics

$15.33 /

+0.02 (+0.13%)

G1 Therapeutics announced…

G1 Therapeutics announced the grant of inducement stock options exercisable for an aggregate of 43,400 shares of G1's common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. The stock options were granted as an inducement material to the new employee's becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1, as an inducement material to such individual's entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The stock options are exercisable at a price of $15.32 per share, the closing price of G1's common stock on September 1, 2021, the grant date. Each stock option has up to a ten-year term and vests over four years, with 25% of the award vesting on the first anniversary of the employee's employment, and as to an additional 1/48th of the shares monthly thereafter, subject to continued service through the applicable vesting dates. The stock options are subject to the terms and conditions of the Inducement Plan.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.33 /

+0.02 (+0.13%)

GTHX G1 Therapeutics
$15.33 /

+0.02 (+0.13%)

08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
11/17/20 Raymond James
G1 Therapeutics downgraded to Outperform from Strong Buy at Raymond James
GTHX G1 Therapeutics
$15.33 /

+0.02 (+0.13%)

Hot Stocks
Black Diamond Therapeutics announces appointment of Velleca to board » 08:02
08/10/21
08/10
08:02
08/10/21
08:02
BDTX

Black Diamond Therapeutics

$9.84 /

+0.045 (+0.46%)

, GTHX

G1 Therapeutics

$15.64 /

-0.35 (-2.19%)

Black Diamond…

Black Diamond Therapeutics (BDTX) announced the appointment of Mark Velleca, M.D., Ph.D. to its board of directors. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics. Velleca was most recently Chief Executive Officer of G1 Therapeutics (GTHX), where he grew the company from Series A through IPO and led the development of its first therapy from preclinical to FDA approval.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.64 /

-0.35 (-2.19%)

BDTX Black Diamond Therapeutics
$9.84 /

+0.045 (+0.46%)

BDTX Black Diamond Therapeutics
$9.84 /

+0.045 (+0.46%)

05/21/21 Wedbush
Black Diamond Therapeutics removed from Best Ideas List at Wedbush
03/29/21 Wedbush
Black Diamond Therapeutics added to Best Ideas List at Wedbush
01/07/21 Wedbush
Wedbush bullish on Black Diamond Therapeutics, initiates with an Outperform
01/06/21 Wedbush
Black Diamond Therapeutics initiated with an Outperform at Wedbush
GTHX G1 Therapeutics
$15.64 /

-0.35 (-2.19%)

08/05/21 Wedbush
G1 Therapeutics price target lowered to $38 from $59 at Wedbush
04/23/21 Cowen
G1 Therapeutics transferred with Outperform at Cowen
11/17/20 Raymond James
Raymond James downgrades G1 Therapeutics after removing rintodestrant from model
11/17/20 Raymond James
G1 Therapeutics downgraded to Outperform from Strong Buy at Raymond James
GTHX G1 Therapeutics
$15.64 /

-0.35 (-2.19%)

BDTX Black Diamond Therapeutics
$9.84 /

+0.045 (+0.46%)

BDTX Black Diamond Therapeutics
$9.84 /

+0.045 (+0.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.